来源：新浪证券-红岸工作室 2月4日，威高血净涨0.17%，成交额3662.68万元，换手率2.32%，总市值168.15亿元。 异动分析 医疗器械概念+注册制次新股+一带一路+新股与次新股+股权转让(并购重组) 1、山东威高血液净化制品股份有限公司的主营业务为血液净化医用制品的研发、生产和销售。公司主 要产品包括血液透析器、血液透析管路、血液透析机以及腹膜透析液，分别围绕血液透析和腹膜透析领 域，辅以透析配套产品的销售，是国内产品线最为丰富的血液净化医用制品厂商之一。 2、山东威高血液净化制品股份有限公司于2025-05-19日上市，主营业务为血液净化医用制品的研发、 生产和销售。 今日主力净流入-203.87万，占比0.06%，行业排名89/135，连续3日被主力资金减仓；所属行业主力净流 入-1.09亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-203.87万-271.04万-479.11万-2631.40万-8051.46万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额725.99万，占总成交额的2.97%。 技术面：筹码平均交易成本为41.25元 3、2025 ...

本报讯(记者冯雨瑶) 山外山表示，作为国产血液净化设备的龙头企业，报告期内，依托技术领先优势和强大的品牌效应，公 司产品市场占有率持续提升，推动了血液净化设备销售收入的稳步增长；同时，自产的血液净化耗材销 售收入亦大幅提升。随着产销量的提升，自产耗材单位固定成本进一步下降，毛利率提升，公司总体盈 利能力进一步增强。 1月30日晚间，重庆山外山血液净化技术股份有限公司(以下简称"山外山")发布2025年度业绩预告，经 财务部门初步测算，预计2025年实现归属于母公司所有者的净利润 1.40亿元至1.59亿元，同比大幅增长98%至125%；预计实现归属于母公司所有者的扣除非经常性损益的 净利润1.34亿元至1.54亿元，同比增长135%至170%。 山外山是专业从事血液净化设备与耗材的研发、生产和销售，并提供连锁血液透析医疗服务的国家高新 技术企业。公司基于原创性血液净化设备的关键核心技术，研发了连续性血液净化设备(CRRT)、血液 透析机以及血液灌流机，并自主研发了血液透析浓缩液、血液透析干粉、血液透析器、透析液过滤器、 连续性血液净化管路、一次性使用血液灌流器等血液净化耗材，产品广泛应用于治疗各类急慢性肾功能 ...

1月19日，寒雪突降，位于新乡市凤泉区的河南知微生物医药有限公司（以下简称"知微医药"）实验室里却是 一派热火朝天。精密仪器高速运转，科研人员全神贯注地调试数据、记录反应。这里，针对不同液体肿瘤、 实体瘤和自身免疫性疾病等适应证的十条创新药管线正齐头并进。 "看，这就是我们的'撒手锏'——自主研发的I类创新药BTK抑制剂TM471-1，目前已有一个适应证进入二期临 床，另有多个适应证也将陆续进入二期临床。"知微医药总经理李伟指着实验报告告诉记者，"其中，利用 BTK抑制剂治疗自身免疫性脑炎，更是全球首创。" 距离知微生物7公里外，北京恒峰铭成生物有限公司河南研发生产基地一片繁忙。落户新乡不到3年，这家企 业的干细胞治疗2型糖尿病方向，已通过国家药监局许可进入临床一期，不仅填补了省内空白，更为产业发展 注入前沿动能。"一开春，我们就将启动类风湿关节炎、糖尿病肾病方向干细胞新药研发。"企业负责人介 绍。 医疗耗材是新乡的亮丽名片之一。在"中国医疗耗材之都"长垣，企业也不再满足于占据全国六成市场份额 的"舒适区"，正奋力向高端设备、高值耗材、体外诊断等领域拓展，开辟新的增长曲线。驼人集团历时五年 攻克八项关键核心技 ...

Core Viewpoint - Weigao Blood Purification is acquiring 100% equity of Weigao Prue from Weigao Group and other parties for 8.511 billion yuan, raising concerns about potential asset stripping of Weigao Shares and the implications of this transaction on the company's structure and valuation [1][4]. Group 1: Transaction Details - Weigao Blood Purification plans to purchase Weigao Prue, a subsidiary of Weigao Shares, which will become a wholly-owned subsidiary post-transaction [1][2]. - The acquisition price of 8.511 billion yuan is based on Weigao Prue's projected net profit of 5.81 billion yuan for 2024, resulting in a P/E ratio of 14.66, compared to Weigao Shares' dynamic P/E ratio of around 11 [6]. Group 2: Financial Performance - Weigao Prue has shown strong financial performance, with projected revenues of 14.30 billion yuan, 16.73 billion yuan, and 14.12 billion yuan for 2023, 2024, and the first nine months of 2025, respectively [2]. - The net profits for the same periods are projected to be 4.83 billion yuan, 5.81 billion yuan, and 4.86 billion yuan, indicating that Weigao Prue's profitability is 1.29 times that of Weigao Blood Purification in 2024 [2][5]. Group 3: Strategic Implications - The transaction is seen as a strategic move to consolidate quality assets and enhance the profitability and investment value of Weigao Blood Purification, while also raising concerns about the potential for Weigao Shares to be stripped of its core assets [4][5]. - Following the acquisition, Weigao Blood Purification's earnings per share are expected to increase significantly, with projected basic earnings per share of 1.60 yuan and 1.25 yuan for 2024 and the first nine months of 2025, respectively, reflecting increases of 32% and 47% [6]. Group 4: Market Position and Challenges - Weigao Blood Purification holds a leading market share in the domestic blood dialysis device sector, with 32.5% for blood dialysis machines and 31.8% for blood dialysis tubing in 2023 [7]. - The company faces challenges from centralized procurement policies, which may pressure product prices and impact future revenue growth, as evidenced by a decline in average factory prices for related products [7][8].

Core Viewpoint - Weigao Blood Purification is acquiring 100% equity of Weigao Prue from Weigao Group and other parties for 8.511 billion yuan, raising concerns about potential asset stripping of Weigao Group and the rationale behind this significant restructuring shortly after Weigao Blood Purification's A-share listing [1][20]. Group 1: Transaction Details - The acquisition involves Weigao Blood Purification purchasing Weigao Prue, a subsidiary of Weigao Group, which will become a wholly-owned subsidiary post-transaction [3][21]. - Weigao Prue, established in September 2018, is a leader in pre-filled syringe systems, holding over 50% market share in China from 2022 to 2024, and ranks among the top five globally [21][22]. - Financial projections indicate that Weigao Prue will significantly enhance Weigao Blood Purification's profitability, with expected revenues of 14.30 billion yuan, 16.73 billion yuan, and 14.12 billion yuan for 2023, 2024, and the first nine months of 2025, respectively [21][22]. Group 2: Historical Context and Ownership Changes - Weigao Blood Purification was originally established in December 2004 with Weigao Group as a major shareholder, holding a 70% stake at inception [4][22]. - In November 2019, Weigao Blood Purification's registered capital increased to 2.9907 billion yuan, with Weigao Group becoming the largest shareholder [5][24]. - The restructuring marks a return of Weigao Blood Purification under Weigao Group's control, raising questions about the implications for minority shareholders and the potential for asset stripping [6][25]. Group 3: Valuation and Financial Impact - The acquisition price of 8.511 billion yuan reflects a significant premium, with an estimated valuation increase of over 5.6 billion yuan for Weigao Prue, resulting in a 192.9% appreciation [10][29]. - The price-to-earnings ratio for the acquisition is calculated at 14.66 times based on Weigao Prue's projected net profit of 5.81 billion yuan for 2024, compared to Weigao Group's current P/E ratio of around 11 [10][29]. - Post-acquisition, Weigao Blood Purification's earnings per share are expected to rise by 32% and 47% for the years 2024 and the first nine months of 2025, respectively [10][30]. Group 4: Market Position and Challenges - Weigao Blood Purification holds a leading market share of 32.5% in the domestic blood dialysis device sector and 31.8% in blood dialysis tubing [31][32]. - The company faces challenges from centralized procurement policies, which may pressure prices and impact future revenue growth [32][33]. - Despite price pressures, the company has seen a growth in sales volume, although revenue growth has slowed to 3.45% as of Q3 2023, down from a peak of 17.71% in 2022 [36].

Core Insights - The article emphasizes the increasing demand for hemodialysis machines driven by the rising global burden of kidney diseases and the integration of advanced technologies in treatment [1][2][3] Group 1: Market Demand and Growth - The global market for hemodialysis machines is projected to reach USD 2.05 billion by 2031, with a compound annual growth rate (CAGR) of 6.6% [3] - Chronic kidney disease management is becoming a significant public health issue, leading to the expansion of both public and private dialysis centers [1][2] - The demand for hemodialysis machines is supported by improvements in healthcare policies, increased accessibility to dialysis, and infrastructure development in emerging markets [1][2] Group 2: Industry Challenges - The industry faces challenges such as cost pressures, stricter regulatory requirements, and supply chain security issues [2] - Key components like pump valves, sensors, and electronic systems are experiencing significant cost fluctuations, impacting profitability [2] - The shift towards centralized procurement policies in some regions is intensifying price competition, putting pressure on smaller companies [2] Group 3: Technological Advancements - Major manufacturers are focusing on the acceleration of automation and smart technology, enhancing treatment precision and reducing operational costs [1][2] - The demand for interconnected devices and digital management systems is increasing, shifting the focus from individual machine performance to overall treatment quality and efficiency [2] Group 4: Market Structure - The top five manufacturers hold approximately 82.0% of the global market share, indicating a highly concentrated market [6] - Single-pump hemodialysis machines dominate the product type segment, accounting for about 77.7% of the market [9] - Hospitals represent the largest downstream market for hemodialysis machines, making up approximately 57.6% of the demand [12]

Group 1: Major Asset Restructuring - Yingfang Micro announced plans to acquire controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd., which is expected to constitute a major asset restructuring [1][5] - The transaction will involve a combination of issuing shares and/or cash payments, with the company’s stock set to be suspended from trading starting January 6, 2026, due to uncertainties surrounding the deal [2][5] - Yingfang Micro is required to disclose the transaction plan within 10 trading days, by January 20, 2026, and if not, the stock will resume trading on that date with a termination of the restructuring plans [5] Group 2: Financial Details and Market Impact - As of January 5, 2026, Yingfang Micro's stock price increased by 4.74% to 7.73 yuan, with a total market capitalization of 6.528 billion yuan [6] - The company specializes in the distribution of electronic components and the research, design, and sales of integrated circuit chips, including RF chips, fingerprint chips, power chips, and storage chips [6] Group 3: Weigao Blood Purification's Acquisition - Weigao Blood Purification announced plans to issue shares to acquire 100% of Weigao Puri Pharmaceutical Packaging Co., Ltd. for approximately 8.511 billion yuan, constituting a major asset restructuring and related party transaction [7][8] - The acquisition will not change the control of Weigao Blood Purification, as the controlling shareholder remains the same [7][8] - Weigao Puri, established in September 2018, focuses on the development and production of pre-filled drug delivery systems and automatic safety drug delivery systems, which will expand Weigao Blood Purification's product offerings [9] Group 4: Market Position and Future Prospects - Weigao Blood Purification holds the leading market share in the domestic blood dialysis sector, with 32.5% in blood dialysis devices and 31.8% in blood dialysis tubing [9] - The acquisition is expected to leverage synergies between Weigao Blood Purification's existing technology and Weigao Puri's customer resources, enhancing their capabilities in the biopharmaceutical filter market [10]

Group 1: 盈方微重大资产重组 - 盈方微 is planning to acquire controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd., which is expected to constitute a major asset restructuring [2][6] - The company will suspend its stock trading starting January 6, 2026, due to the ongoing planning of the acquisition [3][6] - The transaction is not classified as a related party transaction or a restructuring listing, and the company aims to disclose the transaction plan within 10 trading days, by January 20, 2026 [6][7] Group 2: 威高血净重大资产重组 - 威高血净 plans to issue shares to acquire 100% equity of 威高普瑞 from 威高股份, 威海盛熙, and 威海瑞明 for approximately 8.511 billion yuan, which constitutes a major asset restructuring and a related party transaction [8][9] - After the transaction, 威高股份 and its concerted parties will hold 84.36% of 威高血净's shares, maintaining absolute control over the company [9] - The acquisition will expand 威高血净's business into the development, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, enhancing its product line in the pharmaceutical packaging sector [10][11]

Group 1: 盈方微重大资产重组 - 盈方微 is planning to acquire controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd., which is expected to constitute a major asset restructuring [1][3] - The acquisition will be conducted through a combination of issuing shares and/or cash payments, and the company has announced a stock suspension starting January 6, 2026, due to uncertainties surrounding the transaction [2][3] - The company aims to disclose the transaction plan within 10 trading days, by January 20, 2026, and if not completed, the stock will resume trading on January 20, 2026, and the restructuring plans will be terminated [3] Group 2: 威高血净重大资产重组 - 威高血净 plans to issue shares to acquire 100% equity of 威高普瑞 from 威高股份, 威海盛熙, and 威海瑞明 for approximately ¥85.11 billion, which constitutes a major asset restructuring and related party transaction [8][9] - After the transaction, 威高股份 and its concerted parties will hold 84.36% of 威高血净's shares, maintaining absolute control over the company [9] - 威高普瑞, established in September 2018, specializes in the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, which will expand 威高血净's product offerings in the pharmaceutical packaging sector [10][11]

Group 1: 盈方微重大资产重组 - 盈方微 is planning to acquire controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd., which is expected to constitute a major asset restructuring [1][6] - The acquisition will be conducted through a combination of issuing shares and/or cash payments, and the company has applied for a trading suspension starting January 6, 2026, due to uncertainties surrounding the transaction [3][7] - The company aims to disclose the transaction plan within 10 trading days, by January 20, 2026, and if not completed, the stock will resume trading on January 20, 2026, and the restructuring plans will be terminated [6][7] Group 2: 威高血净重大资产重组 - 威高血净 plans to issue shares to acquire 100% equity of 威高普瑞 from 威高股份 and other shareholders for approximately 85.11 billion CNY, which constitutes a major asset restructuring and related party transaction [12][13] - Post-transaction, 威高股份 and its concerted parties will hold 84.36% of 威高血净, maintaining absolute control without changing the company's control structure [12][13] - The acquisition will expand 威高血净's business into the pharmaceutical packaging sector, adding pre-filled drug delivery systems and automatic safety drug delivery systems to its product line [13][14]